« Return to News | R&D Trends

Catalent, Biota Pharmaceuticals expand alliance

Tuesday, July 16, 2013 09:30 AM

Catalent Pharma Solutions, a global development solutions and advanced drug delivery technologies company, and Biota Pharmaceuticals have allied to develop and provide filling and packaging capabilities to supply clinical trial materials of laninamivir octanoate, a first-in-class, inhaled, long-acting neuraminidase inhibitor being developed by Biota to treat influenza A and B viruses.

In 2012, Catalent began working with Biota on inhaled formulation feasibility studies and device filling and analytical support from its development and analytical facilities, located in Research Triangle Park, N.C. Catalent also provides clinical packaging services from its specialty Clinical Supply Services facility in Philadelphia, Penn., for Biota's dry powder inhaler, which is used to administer laninamivir octanoate.

Catalent has a range of development services across all inhaled dose forms and advances inhalation products to market. Catalent will invest $20 million to expand the capabilities of its Inhalation Center of Excellence, which will support customers such as Biota in meeting demand for advanced inhalation dose forms.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.